Sangamo Therapeutics, Inc. (SGMO)

US — Healthcare Sector

Peers: VYGR QURE ALLO EDIT NTLA ALNY

Automate Your Wheel Strategy on SGMO

With Tiblio's Option Bot, you can configure your own wheel strategy including SGMO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol SGMO
Rev/Share 0.2894
Book/Share 0.0223
PB 24.1147
Debt/Equity 5.0705
CurrentRatio 0.7586
ROIC -2.238

MktCap 131805414.0
FreeCF/Share -0.2038
PFCF -2.9361
PE -1.4891
Debt/Assets 0.2887
DivYield 0
ROE -3.5116

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 5
P/B Score 1
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Upgrade	SGMO	Truist	Hold	Buy	--	$7	Dec. 13, 2024
Reiterated	SGMO	H.C. Wainwright	--	Buy	--	$10	Dec. 10, 2024

News

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

SGMO
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 EARNINGS CALL.

image for news Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

LLY, SGMO
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive

Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025.

image for news Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

About Sangamo Therapeutics, Inc. (SGMO)

IPO Date 2000-04-06
Website https://www.sangamo.com
Industry Biotechnology
CEO Alexander D. Macrae Ch.B, M.B., MRCP,
Employees 183

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.